Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

Talazoparib (Talzenna) is a novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor that is clinically used for the therapy of breast cancer. Furthermore, the drug has shown antitumor activity against different cancer types, including non-small cell lung cancer (NSCLC). In this work, w...

Full description

Bibliographic Details
Main Authors: Ziba Sabet, Dimitrios Vagiannis, Youssif Budagaga, Yu Zhang, Eva Novotná, Ivo Hanke, Tomáš Rozkoš, Jakub Hofman
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:International Journal of Molecular Sciences
Subjects:
talazoparib
ABC transporter
small cell lung cancer
multidrug resistance
pharmacokinetic drug–drug interaction
cytochrome P450
Online Access:https://www.mdpi.com/1422-0067/23/22/14338

Internet

https://www.mdpi.com/1422-0067/23/22/14338

Similar Items